The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach-Reference-Cited by-同舟云学术

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Published:2012-09-04 Issue:10 Volume:9 Page:579-590
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Cornelissen Jan J.,Gratwohl Alois,Schlenk Richard F.,Sierra Jorge,Bornhäuser Martin,Juliusson Gunnar,Råcil Zdenek,Rowe Jacob M.,Russell Nigel,Mohty Mohamad,Löwenberg Bob,Socié Gerard,Niederwieser Dietger,Ossenkoppele Gert J.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/nrclinonc.2012.150.pdf

Reference145 articles.

1. Slovak, M. L. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96, 4075–4083 (2000).

2. Burnett, A. K. et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 Trial. Br. J. Haematol. 118, 385–400 (2002).

3. Suciu, S. et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients younger than 46 years old with acute myeloid leukemia (AML) in first complete remission (CR1): an intention to treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 102, 1232–1240 (2003).

4. Yanada, M., Matsuo, K., Emi, N. & Naoe, T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103, 1652–1658 (2005).

5. Cornelissen, J. J. et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109, 3658–3666 (2007).

Cited by 357 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial;Blood Cancer Journal;2024-08-21

2. Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT;Bone Marrow Transplantation;2024-08-20

3. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML;Blood;2024-08-15

4. Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics;European Journal of Haematology;2024-08-11

5. Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients;Bone Marrow Transplantation;2024-05-03